Share

August 07, 2012; 79 (6) Articles

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS

S.E. Bushnell, Z. Zhao, C.C. Stebbins, D. Cadavid, A.M. Buko, E.T. Whalley, J.A. Davis, E.M. Versage, J.R. Richert, R.C. Axtell, L. Steinman, R. Medori
First published May 9, 2012, DOI: https://doi.org/10.1212/WNL.0b013e318259e123
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
424

Share

Article Information

vol. 79 no. 6 531-537
DOI: 
https://doi.org/10.1212/WNL.0b013e318259e123
PubMed: 
22573631
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received October 18, 2011
  • Accepted January 31, 2012
  • First Published May 9, 2012.

Article Versions

Copyright & Usage: 
Copyright © 2012 by AAN Enterprises, Inc.

Author Disclosures

    1. S.E. Bushnell, PhD,
    2. Z. Zhao, MS, MMed,
    3. C.C. Stebbins, PhD,
    4. D. Cadavid, MD,
    5. A.M. Buko, PhD,
    6. E.T. Whalley, PhD,
    7. J.A. Davis, BS,
    8. E.M. Versage, MA,
    9. J.R. Richert, MD,
    10. R.C. Axtell, PhD,
    11. L. Steinman, MD and
    12. R. Medori, MD
  1. S.E. Bushnell, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Sr. Director Translational Medicine, Biogen Idec

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Idec

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Biogen Idec, 2012, 2011

    Stock/Stock Options, Medical Equipment & Materials:

    1. Biogen Idec, 2012, 2011

    Legal Proceedings:

    1. NONE

  2. Z. Zhao, MS, MMed,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am a full time employee of Biogen IDec.

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. C.C. Stebbins, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Biogen Idec, Sr. Scientist

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. D. Cadavid, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I’m a full time paid employee of Biogen Idec and own restricted stock units and stock in Biogen Idec

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. I own stock and restricted stock units as compensation for my full time employment at Biogen Idec

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. I own stock and have been awarded restricted stock units as compensation for my full time employment at Biogen Idec

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. A.M. Buko, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. E.T. Whalley, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am an employee of Biogen Idec.

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. I own stock in Biogen Idec.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. J.A. Davis, BS,
    8. Scientific Advisory Boards:

    1. I am employed by Biogen Idec, Inc.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Currently on the editorial board of the Journal of Neurotherapeutics. I do not receive compensation for this.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am employed by Biogen Idec, Inc.

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. I am employed by Biogen Idec. Some of my compensation is in the form of stock options.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. I am employed by Biogen Idec, Inc. Some of my compensation is in the form of stock options.

    Stock/Stock Options, Medical Equipment & Materials:

    1. I am employed by Biogen Idec, In. Some of my compensation is in the form of stock options.

    Legal Proceedings:

    1. NONE

  8. E.M. Versage, MA,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Biogen Idec, Clinical Operations

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. I own stock in Biogen Idec.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. J.R. Richert, MD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Neurotherapeutics

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am employed by Biogen Idec, Inc.

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. I am employed by Biogen Idec, In. Some of my compensation is in the form of stock options.

    Legal Proceedings:

    1. NONE

  10. R.C. Axtell, PhD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Patent on bio markers predicting response to ifnb treatment

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH-ninds

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. L. Steinman, MD and
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen, Bayhill, Bayer, Cellgene

    Editorial Boards:

    1. MS Journal

    Patents:

    1. I have a patent pending on cytokines and type 1 interferons

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH $01 55997 2010, 2011

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. R. Medori, MD
    13. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am a full time employee of Biogen IDec.

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Biogen Idec (S.E.B., Z.Z., C.C.S., D.C., A.M.B., E.T.W., J.A.D., E.M.V., J.R.R.), Cambridge, MA; Department of Neurology and Neurological Sciences (R.C.A., L.S.), Stanford University, Stanford, CA; and Biogen Idec (R.M.), Zug, Switzerland.
  1. Correspondence & reprint requests to Dr. Bushnell: steven.bushnell{at}biogenidec.com
View Full Text

Article usage

Article usage: May 2012 to May 2023

AbstractFullPdfSource
May 2012309070Highwire
Jun 2012111036Highwire
Jul 201268016Highwire
Aug 201210882353Highwire
Sep 2012145816Highwire
Oct 2012851217Highwire
Nov 2012511010Highwire
Dec 20125168Highwire
Jan 20135816Highwire
Feb 20133434Highwire
Mar 20133542Highwire
Apr 20133847Highwire
May 20132031Highwire
Jun 20133901Highwire
Jul 20131833Highwire
Aug 20131522Highwire
Sep 20131621Highwire
Oct 20131911Highwire
Nov 20131612Highwire
Dec 20131611Highwire
Jan 20142533Highwire
Jan 20140138pmc
Feb 20141121Highwire
Mar 20141312Highwire
Apr 20141511Highwire
May 20142321Highwire
Jun 20141811Highwire
Jul 20142100Highwire
Aug 20142100Highwire
Sep 20141610Highwire
Oct 20141732Highwire
Nov 20141945Highwire
Dec 20141500Highwire
Jan 20151810Highwire
Jan 2015023pmc
Feb 20151802Highwire
Feb 2015084pmc
Mar 20152116Highwire
Mar 2015086pmc
Apr 20151700Highwire
Apr 2015051pmc
May 20151112Highwire
May 2015065pmc
Jun 20151200Highwire
Jun 2015083pmc
Jul 20151303Highwire
Jul 2015042pmc
Aug 20151900Highwire
Aug 2015031pmc
Sep 20151600Highwire
Sep 2015093pmc
Oct 2015711Highwire
Oct 2015081pmc
Nov 20151413Highwire
Nov 20150118pmc
Dec 20153600Highwire
Dec 2015089pmc
Jan 20161721Highwire
Jan 2016023pmc
Feb 2016800Highwire
Feb 2016078pmc
Mar 20162515Highwire
Mar 2016031pmc
Apr 20161710Highwire
Apr 2016051pmc
May 20162023Highwire
May 2016043pmc
Jun 20161900Highwire
Jun 2016074pmc
Jul 20162200Highwire
Jul 2016042pmc
Aug 20162300Highwire
Aug 2016031pmc
Sep 20161700Highwire
Sep 2016020pmc
Oct 20161701Highwire
Oct 2016041pmc
Nov 20161211Highwire
Nov 2016042pmc
Dec 2016900Highwire
Dec 2016020pmc
Jan 20171100Highwire
Jan 2017020pmc
Feb 2017900Highwire
Feb 2017051pmc
Mar 20171400Highwire
Mar 2017021pmc
Apr 20171911Highwire
Apr 2017011pmc
May 2017900Highwire
May 2017011pmc
Jun 2017900Highwire
Jun 2017332pmc
Jul 20171300Highwire
Jul 2017122pmc
Aug 2017500Highwire
Aug 2017122pmc
Sep 2017700Highwire
Sep 2017077pmc
Oct 2017400Highwire
Oct 2017022pmc
Nov 2017500Highwire
Nov 2017011pmc
Dec 2017811Highwire
Jan 2018710Highwire
Feb 20181010Highwire
Mar 2018910Highwire
Apr 2018700Highwire
Apr 2018221pmc
May 20181001Highwire
Jun 20181200Highwire
Jun 2018144pmc
Jul 20181700Highwire
Aug 2018800Highwire
Sep 20181000Highwire
Oct 2018700Highwire
Nov 2018800Highwire
Dec 2018712Highwire
Jan 20191001Highwire
Feb 2019700Highwire
Mar 2019220Highwire
Apr 2019401Highwire
May 20191300Highwire
Jun 2019800Highwire
Jul 2019500Highwire
Aug 2019413Highwire
Sep 20191000Highwire
Oct 20192800Highwire
Nov 20194400Highwire
Dec 20192210Highwire
Jan 20201302Highwire
Feb 2020500Highwire
Mar 2020500Highwire
Apr 2020400Highwire
May 2020700Highwire
Jun 20202900Highwire
Jul 2020701Highwire
Aug 2020510Highwire
Sep 2020900Highwire
Oct 20201200Highwire
Nov 20202210Highwire
Dec 20201200Highwire
Jan 2021800Highwire
Feb 20212200Highwire
Mar 20211601Highwire
Apr 20211300Highwire
May 2021922Highwire
Jun 20214500Highwire
Jul 20211200Highwire
Aug 2021810Highwire
Sep 2021500Highwire
Oct 20211000Highwire
Nov 20211500Highwire
Dec 20211000Highwire
Jan 2022800Highwire
Feb 20221600Highwire
Mar 20221800Highwire
Apr 20221400Highwire
May 20222100Highwire
Jun 2022911Highwire
Jul 20221801Highwire
Aug 2022700Highwire
Sep 20221500Highwire
Oct 20221600Highwire
Nov 20221800Highwire
Dec 20221900Highwire
Jan 20232400Highwire
Feb 20231200Highwire
Mar 20231500Highwire
Apr 20231000Highwire
May 20231000Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles